ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price

… endpoints in trials in the two other indications it had been running besides AAV – C3 glomerulopathy and hidradenitis suppurativa. A few years ago, …

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *